Patents Assigned to Karos Pharmaceuticals, Inc.
  • Processes for preparing (R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethanone
    Patent number: 9611201
    Abstract: The present invention relates to processes for the preparation of (R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethanol, 1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethanone, and intermediates thereof, which are useful in the preparation of inhibitors of TPH1 for the treatment of, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, low bone mass diseases, serotonin syndrome, and cancer.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: April 4, 2017
    Assignee: Karos Pharmaceuticals, Inc.
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg
  • Spirocyclic compounds as tryptophan hydroxylase inhibitors
    Patent number: 9512122
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: December 6, 2016
    Assignee: Karos Pharmaceuticals, Inc.
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Spirocyclic compounds as tryptophan hydroxylase inhibitors
    Patent number: 9199994
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: December 1, 2015
    Assignee: Karos Pharmaceuticals, Inc.
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren